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Transplantation (ASBMT) organized a comprehensive edu-
cation supplement published in Biology of Blood and Marrow
Transplantation in conjunction with the annual BMT Tandem
Meetings, jointly organized by the ASBMT and the Center for
International Blood and Marrow Transplant Research
(CIBMTR). Beginning with last year’s meeting, the education
supplement was condensed to comprise critical reviews of 3
topics, selected by the meeting co-chairs, highlighting topics
of particular interest. This year we are pleased to present 3
outstanding review articles compiled by scientiﬁc session
speakers who are world leaders in their respective disci-
plines that examine topics of broad interest to the transplant
community.
In the ﬁrst review, Drs. Paresh Vyas, Frederick Appelbaum,
and Charles Craddock review the current state of allogeneic
hematopoietic cell transplantation (HCT) for acute myeloid
leukemia (AML). AML remains the leading indication for
allogeneic HCT in the world, with over 25,000 patients
transplanted for this indication in the 10-year span from
2001 to 2011 (source: CIBMTR, 2014). As discussed by the
authors, AML presents both opportunity and persistent
challenge, given the clear importance of the graft-versus-
leukemia response seen after HCT as well as the fact that
the most common cause of death in treated patients remains
therapy-resistant disease.
In this collaborative review, Dr. Vyas ﬁrst presents an
overviewof leukemiabiology.Hedescribesour rapidevolution
from a conventional strategy of AML diagnosis and prognostic
assessment based onmorphologic and cytogenetic evaluation
that guided decisions about transplantation for decades. He
discusses the expanding use of molecular studies, including
emerging studies based on whole genome and exome
sequencing in newly diagnosed AML patients. He also dis-
cusses the important role of clonal heterogeneity within the
leukemic population, including the putative role of leukemic
stem cells in leukemia persistence and treatment failure.Financial disclosure: See Acknowledgments on page S2.
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conditioning as they apply to AML and reviews the pro-
gression of conditioning from intensive combinations of
cytotoxic chemotherapy and radiation to reduced-intensity
therapies. He discusses the challenges of balancing dose in-
tensity, which is protective for relapse, with treatment-
associated morbidity and mortality. He further reviews the
relationship between conditioning and graft-versus-host
disease (GVHD) incidence and discusses emerging strate-
gies that have the potential to improve outcomes.
Finally, Dr. Craddock discusses strategies to optimize
conditioning and minimize relapse (using donor lymphocyte
infusions and/or administration of adjunctive targeted in-
hibitors or epigenetic modulating agents) and the potential
use of combination therapies to maintain remission in the
post-HCT setting.
In the second review, organized and edited by Dr. Jerome
Ritz, Drs. Stephanie Sarantopoulos, Bruce Blazar, and Corey
Cutler review the role of B cells in chronic GVHD. Chronic
GVHD continues to be one of the most frequent and vexing
long-term complications after allogeneic HCT and that most
frequently associated with impairment of quality of life after
transplantation. Although it has long been known that T cells
are critical mediators capable of initiating and maintaining
alloreactivity, a large body of basic and clinical evidence
suggests that B cells play an important role in this syndrome.
Dr. Sarantopoulos ﬁrst reviews translational studies
demonstrating the importance of B cell activation and the
role of B celleactivating factor in the maintenance of autor-
eactive B cell clones important in chronic GVHD pathogen-
esis. She also discusses our emerging understanding of other
signaling cascades (including the AKT and ERK pathways)
and potential actionable targets, including Bruton’s tyrosine
kinase and spleen tyrosine kinase for which inhibitors
are available. She also discusses the critical importance
of crosstalk between B and T cells that maintains both
effector T cell responses and autoantibodies important in
pathogenesis.
Dr. Blazar reviews recently developed models, including
those wherein pulmonary ﬁbrosis results after the interplay
of T follicular helper and germinal center (GC) B cells. He
provides convincing evidence that a broad range of cellular
mechanisms are responsible for GC formation and chronic
GVHD initiation and discusses how drugs that target GC
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transferase) might help. He also discusses how the targeting
of IL-21, spleen tyrosine kinase, Bruton’s tyrosine kinase, and
the related IL-2 inducible kinase may reverse bronchiolitis
obliterans and sclerodermatous manifestations in animal
systems. These studies have yielded a range of antibody and
pharmacologic inhibitors of pathways that may be repur-
posed to treat and/or prevent chronic GVHD in clinical
studies.
Finally, Dr. Cutler reviews current and future clinical
therapies for chronic GVHD, including studies that ﬁrst
established a role for targeting B cells in the treatment of
steroid-refractory GVHD and those establishing anti-HY an-
tibodies as a mediator of chronic GVHD in sex-mismatched
model systems and in human subjects. He discusses how
our understanding of the role of B cells led to the clinical
application of rituximab in both steroid-refractory and the
initial therapy of chronic GVHD failing prophylaxis. He then
discusses the clinical studies conducted to date incorporating
rituximab into strategies designed to prevent, rather than
treat, chronic GVHD.
In the third review, Drs. Michael Boeckh,WilliamMurphy,
and Karl Peggs review recent advances in the pathogenesis
and treatment of cytomegalovirus (CMV) disease. CMV
infection continues to be a frequent cause of post-HCT
morbidity and mortality. Indeed, the lack of nontoxic stra-
tegies for prophylaxis has led to most institutions relying on
preemptive treatment strategies that are imperfect and still
associated with both early and late CMV reactivation and
disease.
Dr. Boeckh reviews the current status of pharmacologic
therapies for CMV, which are ﬁnally progressing beyond the
standard drugs that have proven partially effective but are
associated with such toxicities as myelosuppression and
renal insufﬁciency. He reviews the current status of studies
on several investigational agents with the potential for
improved safety and toxicity proﬁles over currently
approved therapies and their potential for prophylaxis and/
or therapy of end-organ disease.
Dr. Peggs reviews the importance of T cells, which have
been shown in a large number of human translational studies
as important for suppression of CMV reactivation in alloge-
neic HCT recipients. The ﬁrst published report of adoptiveimmunotherapy for CMV in HCT recipients (by Walters,
Riddell and colleagues [1]) appeared nearly 20 years ago. Dr.
Peggs summarizes the substantial progress in the ﬁeld since
that initial report, including the improvement of culture
conditions, and approaches to isolate CMV-speciﬁc T cells
(e.g., using HLA-peptide multimers and isolation of activated
surface cytokine-expressing cells).” In addition to discussing
the theoretical concerns guiding the development of adop-
tive immunotherapy strategies, he discusses recently
completed randomized trials of cellular CMV immunopro-
phylaxis conducted in the United Kingdom.
Finally, Dr. Murphy discusses our expanding under-
standing of natural killer (NK) cells, highlighting compelling
studies in murine models of NK cell development and the
role of NK subsets in the control of experimental infection.
He discusses our emerging understanding of progressively
differentiated and “licensed” NK subsets and the under-
standing that subsets of NK cells exhibit memory-like func-
tions, blurring the classical deﬁnition of NK cells as purely
innate. This review highlights not only the role of NK cells in
control of viral infections but also their likely participation in
regulation of graft-versus-tumor and graft-versus-host
responses.
Overall, these 3 reviews by leading physicians and sci-
entists in the ﬁeld of HCT reﬂect the diverse scientiﬁc and
clinical challenges within HCT and the potential of basic and
translational research to yield improved diagnostic and
therapeutic strategies. On behalf of the ASBMT and CIBMTR,
the scientiﬁc organizing committee, and the expected 3000
attendees of the 2015 BMT Tandem Meetings, we are deeply
grateful for the signiﬁcant efforts of the authors of these
outstanding written reviews and look forward to their
enlightening oral presentations on these topics in San Diego.ACKNOWLEDGMENTS
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